About Eliglustat chemical
We have established ourselves as a renowned manufacturer, exporter and supplier ofEliglustatOur skilled professionals formulate these compounds by making use of various ingredients and chemicals available in the market. We formulate these drugs in our using latest equipmentthereforethese medicines havelongershelf life and are very effective. TheEliglustatis available in various specifications to meet our clients demands.
details:
- Product name:Eliglustat
- Synonyms:benzodioxin-6-yl)-2-hydroxy-1-(1-pyrrolidinylmethyl)ethyl]-octanamide;N-[(1R,2R)-1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(1- pyrrolidinyl)-2-propanyl]octanamide;Eliglustat(Genz-99067)
- CAS NO.: 491833-29-5
- Molecular Formula: C23H36N2O4
- Molecular Weight: 404.54294
Trusted Treatment for Type 1 Gaucher DiseaseEliglustat stands out as an effective oral medication selected for long-term management of type 1 Gaucher disease. Its targeted action helps reduce the burden of harmful lipid accumulation by inhibiting glucosylceramide synthase. Patients benefit from improved quality of life, with reduced symptoms and disease progression.
Exceptional Purity and Quality AssuranceProduced in China, Eliglustat boasts a high purity level of 99%, making it ideal for pharmaceutical use. Stringent quality controls and advanced manufacturing processes ensure the consistent reliability and efficacy of each batch, meeting international standards for therapeutic agents.
Comprehensive Supplier NetworkAs a widely sought-after pharmaceutical ingredient, Eliglustat is distributed globally through reputable exporters, traders, and suppliers based in China. This broad distribution network ensures timely availability and delivery, supporting ongoing therapeutic programs worldwide.
FAQs of Eliglustat chemical:
Q: How is Eliglustat used in the treatment of type 1 Gaucher disease?
A: Eliglustat is administered orally and works by inhibiting the enzyme glucosylceramide synthase, thus reducing the buildup of harmful lipids within cells. This helps manage and alleviate symptoms associated with type 1 Gaucher disease over long-term use.
Q: What is the process for selecting patients for Eliglustat therapy?
A: Patients are selected for Eliglustat treatment based on results from an FDA-approved genotype test. This genetic screening ensures that only individuals who are likely to metabolize the medication safely and effectively are prescribed the therapy.
Q: When should Eliglustat be considered for type 1 Gaucher disease management?
A: Eliglustat is typically considered for patients diagnosed with type 1 Gaucher disease when long-term therapy is indicated and the patients genotype has been confirmed as suitable. This decision is made in consultation with a healthcare professional.
Q: Where is Eliglustat manufactured and distributed from?
A: Eliglustat is produced in China and is distributed internationally by various reputable exporters, distributors, manufacturers, suppliers, and traders. This ensures global access to the pharmaceutical compound.
Q: What benefits does Eliglustat offer compared to other treatments?
A: Eliglustat offers the convenience of oral administration and targets the underlying cause of lipid accumulation in type 1 Gaucher disease. With high purity and reliable therapeutic effect, it can improve clinical symptoms and overall patient outcomes.
Q: What is the purity and chemical composition of Eliglustat?
A: Eliglustat is supplied in powder form with a certified purity of 99%. It has the molecular formula C23H36N2O4 and a CAS number 491833-29-5, ensuring pharmaceutical-grade quality for clinical use.